[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367471-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367471-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-characteristics-and-survival-of-breast-cancer-patients-with-extramammary-malignancies-in-a-single-asian-center-over-the-past-23-years","Clinical characteristics and survival of breast cancer patients with extramammary malignancies in a single Asian center over the past 23 years","","Background explores how multiple primary malignant neoplasms (MPMNs) drive cancer risk, noting that evidence for breast cancer with MPMNs is often limited by small case reports. This long-term study analyzes 280 breast cancer patients with extramammary primary malignancies from January 2000 to December 2022. Methods compare first and second primary breast cancer subgroups under a median 107-month follow-up, excluding stage IV. Results identify predominant double primary malignant neoplasms and assess prognostic factors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-characteristics-and-survival-of-breast-cancer-patients-with-extramammary-malignancies-in-a-single-asian-center-over-the-past-23-years/367471/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-characteristics-and-survival-of-breast-cancer-patients-with-extramammary-malignancies-in-a-single-asian-center-over-the-past-23-years/367471.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study purpose regarding MPMNs and breast cancer?","Question",{"text":63,"@type":64},"The study aimed to scrutinize breast cancer patients who also had extramammary primary malignancies, focusing on multiple primary malignant neoplasms and long-term outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected and what follow-up duration was used?",{"text":68,"@type":64},"The analysis reviewed 280 breast cancer cases with extramammary primary malignancies from January 2000 to December 2022, excluding stage IV breast cancer, with a median follow-up of 107 months.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors predicted poor prognosis in double primary malignant neoplasms (DPMNs)?",{"text":72,"@type":64},"Synchronous cancer, ER/PR-negative status, and advanced extramammary malignancy stage indicated poor prognosis among DPMNs patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367471,1790211954,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Research  \nClinical characteristics and survival of breast cancer patients with extramammary malignancies in a single Asian center over the past 23 years  \nBei Sun1,2,3,4,5,6,7 · Yaoyao Jing2,3,4,5,6 · Yang Wang2,3,4,5,6 · Haiyan Wang2,3,4,5,6 · Xinyue Zhang3,4,5,6,7 · Jin Zhang3,4,5,6,8 · Feng He1  \nReceived: 25 December 2024 / Accepted: 18 March 2025  \n© The Author(s) 2025 OPEN  \nAbstract  \nBackground The rise of multiple primary malignant neoplasms (MPMNs) necessitates exploration. MPMNs represent 18% of U.S. cancers. Breast cancer is the predominant malignancy among female Americans. However, most studies on breast cancer with MPMNs are confined to case reports with small sample sizes. Hence, this article scrutinizes 280 patients diagnosed with breast cancer and extramammary primary malignancies via long-term follow-up.  \nMethods We reviewed 280 breast cancer cases with extramammary primary malignancies from January 2000 to December 2022 at our institute, excluding those diagnosed with stage IV breast cancer. The double primary malignant neoplasms (DPMNs) were used as focal points and segregated into the first primary breast cancer (FPBC) and second primary breast cancer (SPBC) subgroups. With a median follow-up period of 107 months (8.9 years), we examined the characteristics of these diseases in various patients.  \nResults Concerning breast cancer patients with extramammary primary malignancies, DPMNs were predominant, comprising 77.1%(216/280). Among these DPNMs, gynecology, thyroid, and lung were the primary site of extramammary tumors, predominantly. Nearly all (93.9%) of FPBC patients exhibited metachronous cancer whereas 55.9% of SPBC patients experienced this. The median interval between the onset of breast cancer and extramammary malignancy in metachronous FPBC and metachronous SPBC patients was 60 months and 48 months, respectively. Over time, both metachronous FPBC and metachronous SPBC patients demonstrated a diminishing prevalence of second tumors. The distinction lay in that in the metachronous FPBC group, second tumors ceased to occur after 300 months, whereas in the metachronous SPBC group, their emergence persisted. Synchronous cancer, negative ER/PR status, and advanced extramammary malignancy stage portend poor prognosis among patients with DPMNs.  \nConclusions Careful monitoring of MPMNs necessitates precise guidelines, differing amongst FPBC and SPBC patients. Synchronous cancer, ER/PR-negative, and advanced extramammary malignancy stage indicate poor prognosis in DPMNs patients.  \nBei Sun andYaoyao Jing These authors have contributed equally to this work and share first authorship.  \n* Bei Sun, [sunpei003@sina.com |](sunpei003@sina.com |1Institute of Medical)[1](sunpei003@sina.com |1Institute of Medical)[Institute of Medical](sunpei003@sina.com |1Institute of Medical) Engineering and Translational Medicine, Tianjin University, Tianjin,  \nChina. 2Department of Day Ward, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China. 3Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China. 4Tianjin’s Clinical Research Center for Cancer, Tianjin, China. 5Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. 6Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Tianjin Medical University, Tianjin, China. 7Department of Outpatient Office, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China. 8The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.  \nDiscover Oncology  \n(2025) 16:845  \n| [https://doi.org/10.1007/s12672-025-02162-6](https://doi.org/10.1007/s12672-025-02162-6)  \nKeywords Multiple primary malignant neoplasms · Double primary malignant neoplasms · Breast cancer · Extramammary malignancy  \nAbbreviations  \nMPMNs Multiple primary malignant neoplasms DPMNs Double primary malignant neoplasms FPBC First primary breast can","cbCaiiB8nhrBTlc8","https://ap.wps.com/l/cbCaiiB8nhrBTlc8","pdf",1678836,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Methods","[{\"question\":\"What was the study purpose regarding MPMNs and breast cancer?\",\"answer\":\"The study aimed to scrutinize breast cancer patients who also had extramammary primary malignancies, focusing on multiple primary malignant neoplasms and long-term outcomes.\"},{\"question\":\"How were patients selected and what follow-up duration was used?\",\"answer\":\"The analysis reviewed 280 breast cancer cases with extramammary primary malignancies from January 2000 to December 2022, excluding stage IV breast cancer, with a median follow-up of 107 months.\"},{\"question\":\"Which factors predicted poor prognosis in double primary malignant neoplasms (DPMNs)?\",\"answer\":\"Synchronous cancer, ER/PR-negative status, and advanced extramammary malignancy stage indicated poor prognosis among DPMNs patients.\"}]","Clinical characteristics and survival of breast cancer patients with extramammary malignancies in a single Asian center over the past 23 years | PDF",1790170948,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f591a169d0b82511a0eb56d61ec588e6.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60046aa6e7a068b77f63298900335a5c.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/607668027c9cb97490db40b1834900ff.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3aed20abd4833d019969832e44756882.webp",980,1301]